Pricing Log in Create free account
Saturday 17 October 2026 Export ZTS’s income statement to Excel — free account

Zoetis Inc.

ZTS Healthcare Drug Manufacturers Specialty & Generic

Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 2.48%, free cash flow grew 17.4% and total debt rose 37.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.

79.20 0.78 +0.99%
Market cap
$32.4B
P/E
13.0×
Fwd P/E
12.3×
Dividend yield
2.64%
F-score
7/9
Altman Z
5.73
Beneish M
−2.45
Dividend safety
88/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Zoetis Inc. (ZTS) P/B ratio

Alert me on P/B ratio

As of 16 October 2026, Zoetis Inc. (ZTS) trades at a P/B ratio of 10.5×. Over the past ten years it has ranged from 9.2× (October 2026) to 26.3× (September 2020); the current reading is higher than 5% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 1.8× and above the Healthcare sector median of 2.3×.

P/B ratio, daily

Embed this chart

Annual newest first

Period P/B ratio Change
FY2025 16.3× 5.31%
FY2024 15.5× (14.58%)
FY2023 18.2× 16.14%
FY2022 15.6× (38.61%)
FY2021 25.5× 22.13%
FY2020 20.9× (10.74%)
FY2019 23.4× 23.57%
FY2018 18.9× (3.94%)
FY2017 19.7× 11.09%
FY2016 17.7× (19.26%)

Quarterly newest first

Period P/B ratio Change
Jun 2026 9.5× (38.23%)
Mar 2026 15.4× (5.54%)
Dec 2025 16.3× 36.09%
Sep 2025 12.0× (13.92%)
42 more quarters

Against its own ten years

Low 9.2× High 26.3×
Ten-year median 18.2×
Current reading's percentile 5

P/B ratio against peers

Company P/B ratio
TAK Takeda Pharmaceutical Co. compare 1.3×
VTRS Viatris Inc. compare 1.5×
ELAN Elanco Animal Health Incorporated compare 1.8×
HLN Haleon PLC Sponsored ADR compare 2.1×
RDY Dr. Reddy's Laboratories Ltd compare 2.5×
UTHR United Therapeutics Corporation compare 3.5×
NBIX Neurocrine Biosciences, Inc. compare 3.7×
TEVA Teva Pharmaceutical Industries Ltd. compare 6.2×
ZTS Zoetis Inc. 10.5×
Drug Manufacturers Specialty & Generic industry median 1.8×
Healthcare sector median 2.3×
Market median 1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on ZTS